<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mometasone (oral inhalation): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mometasone (oral inhalation): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mometasone (oral inhalation): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9779" href="/d/html/9779.html" rel="external">see "Mometasone (oral inhalation): Drug information"</a> and <a class="drug drug_patient" data-topicid="12257" href="/d/html/12257.html" rel="external">see "Mometasone (oral inhalation): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9461865"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Asmanex (120 Metered Doses);</li>
<li>Asmanex (14 Metered Doses);</li>
<li>Asmanex (30 Metered Doses);</li>
<li>Asmanex (60 Metered Doses);</li>
<li>Asmanex (7 Metered Doses) [DSC];</li>
<li>Asmanex HFA</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871103"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Asmanex Twisthaler</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10502944"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Corticosteroid, Inhalant (Oral)</span>;</li>
<li>
<span class="list-set-name">Glucocorticoid</span></li></ul></div>
<div class="block dop drugH1Div" id="F9461973"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma: Note:</b> Asmanex Twisthaler (110 mcg and 220 mcg Twisthaler) deliver 100 and 200 mcg mometasone furoate per actuation respectively; NAEPP uses doses based on delivery dose, while manufacturer recommended doses are based on inhaler amount. Maximum effects may not be evident for 1 to 2 weeks or longer; higher doses may provide additional asthma control in patients who do not respond adequately after 2 weeks of therapy. Doses should be titrated to the lowest effective dose once asthma is controlled.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Asmanex Twisthaler (dry powder inhaler):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 4 to 11 years (regardless of prior therapy): <b>Note:</b> Use 110 mcg inhaler: Oral inhalation (110 mcg/inhalation): Initial: 110 mcg once daily, administered in the evening. Maximum daily dose: 110 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Dosing based on previous asthma therapy:</p>
<p style="text-indent:-2em;margin-left:10em;">Patients previously treated with bronchodilators alone or with inhaled corticosteroids: Oral inhalation (220 mcg/inhalation): Initial: 220 mcg once daily, administered in the evening; may increase dose after 2 weeks if adequate response not obtained. Maximum daily dose: 440 mcg/<b>day</b>; may be administered as 1 inhalation twice daily or 2 inhalations once daily in the evening.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients previously treated with oral corticosteroids: Oral inhalation (220 mcg/inhalation): Initial: 440 mcg twice daily. Maximum daily dose: 880 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Asmanex HFA:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 5 to &lt;12 years: Oral inhalation (50 mcg/inhalation): 100 mcg twice daily; maximum daily dose: 200 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: <b>Note</b>: Dosing based on previous asthma therapy:</p>
<p style="text-indent:-2em;margin-left:10em;">Patients previously treated with inhaled medium dose corticosteroid: Oral inhalation (100 mcg/inhalation): 200 mcg twice daily; maximum daily dose: 800 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients previously treated with high-dose inhaled corticosteroids or oral corticosteroids: Oral inhalation (200 mcg/inhalation): 400 mcg twice daily; maximum daily dose: 800 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Asthma guidelines:</p>
<p style="text-indent:-2em;margin-left:8em;">Global Initiative for Asthma Guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.3'])">Ref</a></span>): Dry powder inhaler (refers to Asmanex Twisthaler 110 mcg and 220 mcg strengths):</p>
<p style="text-indent:-2em;margin-left:10em;">Children 6 to 11 years: Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:12em;">“Low” dose: 110 mcg/day.</p>
<p style="text-indent:-2em;margin-left:12em;">“Medium” dose: ≥220 to &lt;440 mcg/day.</p>
<p style="text-indent:-2em;margin-left:12em;">“High” dose: ≥440 mcg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:12em;">“Low” dose: 110 to 220 mcg/day.</p>
<p style="text-indent:-2em;margin-left:12em;">“Medium” dose: &gt;220 to 440 mcg/day.</p>
<p style="text-indent:-2em;margin-left:12em;">“High” dose: &gt;440 mcg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">National Asthma Education and Prevention Program (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>): Dry powder inhaler (refers to Asmanex Twisthaler 220 mcg strength): Children ≥12 years and Adolescents: Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:10em;">"Low" dose: 200 mcg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">"Medium" dose: 400 mcg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">"High" dose: &gt;400 mcg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild flare, exacerbation:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents with mild to moderate asthma, no prior history of life-threatening asthma exacerbations, and with good self-management skills:</p>
<p style="text-indent:-2em;margin-left:8em;">It is recommended to temporarily quadruple the inhaled corticosteroid dose early in the course of a mild flare to decrease the severity of an asthma exacerbation. After symptoms stabilize or after a maximum of 14 days of quadrupled dose, whichever occurs first, patients should be returned to their baseline dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>). Quadrupling the inhaled corticosteroid dose has been shown to decrease the severity of an asthma exacerbation in select patients. In a randomized trial of adolescents ≥16 years and adults (n=1,871), temporarily quadrupling the inhaled corticosteroid dose when asthma control began to deteriorate resulted in fewer severe asthma exacerbations (ie, less treatment with systemic glucocorticoids or unscheduled appointments for asthma) compared to patients who maintained their inhaled corticosteroid dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29504499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29504499'])">Ref</a></span>). No data for quadrupling the dose in patients &lt;16 years of age has been published. Quintupling the dose of inhaled corticosteroids (fluticasone) in children 5 to 11 years of age was not shown to reduce the rate of severe exacerbations and may have been associated with adverse effects (decreased linear growth, particularly in patients &lt;8 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-29504498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-29504498'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from oral systemic corticosteroids to orally-inhaled corticosteroids:</i> When using mometasone oral inhalation to help reduce or discontinue oral corticosteroid therapy, begin prednisone taper after at least 1 week of mometasone inhalation therapy; prednisone should be tapered slowly (ie, no faster than 2.5 mg/day on a weekly basis); monitor patients for signs of asthma instability and adrenal insufficiency; decrease mometasone to lowest effective dose after prednisone reduction is complete.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130326"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51130327"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, mometasone exposure may increase with severity of hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F9461974"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9779" href="/d/html/9779.html" rel="external">see "Mometasone (oral inhalation): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ebd9659-c25b-4961-8c64-4b95099e6592">Asthma, maintenance/controller</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance/controller: Note:</b>
<b>Product selection:</b> Individualize daily mometasone dose based on severity of symptoms, typically as follows: low doses for mild persistent asthma; low to medium doses for moderate persistent asthma; and medium to high doses for severe persistent asthma. Select a product with a favorable dosage per actuation to improve convenience and adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Dosage Classification for Mometasone Preparations<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">Low to medium dose</p></th>
<th align="left">
<p style="text-indent:0em;">High dose</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> GINA 2023</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Mometasone</p></td>
<td align="left">
<p style="text-indent:0em;">200 to 400 mcg/day</p></td>
<td align="left">
<p style="text-indent:0em;">&gt;400 mcg/day</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Asmanex HFA: Metered-dose inhaler:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who are not on an inhaled corticosteroid:</i>
<b>Oral inhalation: </b>Mometasone 100 mcg: Initial: 200 mcg twice daily; maximum dose: 800 mcg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients currently receiving chronic oral corticosteroids:</i>
<b>Oral inhalation: </b>Mometasone 200 mcg: Initial: 400 mcg twice daily; maximum dose: 800 mcg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Asmanex Twisthaler: Dry powder inhaler: <b>Note:</b> The 440 mcg daily dose may be administered in divided doses or as once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who previously received bronchodilators alone:</i>
<b>Oral inhalation: </b>Initial: <b></b>220 mcg once daily in the evening; maximum dose: 440 mcg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who previously received inhaled corticosteroids:</i>
<b>Oral inhalation: </b>Initial: <b></b>220 mcg once daily in the evening; maximum dose: 440 mcg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who previously received oral corticosteroids: </i>
<b>Oral inhalation: </b> Initial: 440 mcg twice daily; maximum dose: 880 mcg/day. <b>Note:</b> Prednisone should be reduced slowly (ie, no faster than 2.5 mg daily on a weekly basis), beginning after at least 1 week of mometasone therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990974"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988344"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, mometasone exposure may increase with severity of hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F9461917"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (3% to 22%), fatigue (1% to 13%), depression (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral candidiasis (≤22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (8% to 22%), arthralgia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (3% to 22%), allergic rhinitis (adolescents &amp; adults 14% to 20%; children 4%), upper respiratory tract infection (8% to 15%), pharyngitis (8% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Pain (1% to &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 6%), dyspepsia (5%), nausea (3%), vomiting (1% to ≤3%), anorexia (1% to &lt;3%), gastroenteritis (1% to &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (9%), urinary tract infection (children 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (children 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (4%), infection (1% to &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (6%), myalgia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Increased intraocular pressure (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (1% to &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Paranasal sinus congestion (9%), nasopharyngitis (5% to 8%), bronchitis (3%), dry throat (1% to &lt;3%), epistaxis (1% to &lt;3%), flu-like symptoms (1% to &lt;3%), nasal discomfort (1% to &lt;3%), voice disorder (1% to &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Anaphylaxis, angioedema, blurred vision, bronchospasm, cataract, cough, dyspnea, exacerbation of asthma, glaucoma, growth retardation, hypersensitivity reaction, pruritus, skin rash, wheezing</p></div>
<div class="block coi drugH1Div" id="F9461914"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mometasone or any component of the formulation; hypersensitivity to milk proteins (Asmanex Twisthaler only); primary treatment of status asthmaticus or other acute episodes of asthma for which intensive measures are required</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Untreated systemic fungal, bacterial, viral, or parasitic infections; tuberculosis (TB) disease (active TB) or infection (latent TB) of the respiratory tract; ocular herpes simplex.</p></div>
<div class="block war drugH1Div" id="F9461915"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving ≥20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections (particularly gastroenteritis), or other conditions with severe electrolyte loss. Select surgical patients on long-term, high-dose, inhaled corticosteroids should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Paradoxical bronchospasm that may be life-threatening may occur with use of inhaled bronchodilating agents; reaction should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue mometasone and institute alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (eg, allergic dermatitis, anaphylaxis, angioedema, bronchospasm, flushing, pruritus, rash, urticaria) may occur; discontinue use if reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; respiratory tuberculosis (TB) disease (active TB) or infection (latent TB); or untreated viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox or measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intravenous immunoglobulin, respectively, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while continuing therapy. Patients should be instructed to rinse mouth with water (without swallowing) and spit after each use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Appropriate use: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Use is contraindicated in status asthmaticus or during other acute asthma episodes requiring intensive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (eg, antiseizure medication, oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; blurred vision, increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in long-term users.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 cm per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Asmanex Twisthaler: May contain lactose; very rare anaphylactic reactions have been reported in patients with milk protein allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of systemic corticosteroid therapy: A gradual tapering of dose may be required prior to discontinuing therapy; there have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transfer to oral inhaler: When transferring to oral inhalation therapy from systemic corticosteroid therapy, previously suppressed allergic conditions (rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions) may be unmasked. Withdraw systemic corticosteroid therapy by gradually tapering the dose. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (eg, fatigue, lassitude, weakness, nausea/vomiting, hypotension) during withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54018399"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Although recommended in children ≥12 years and adolescents, using higher doses (quintupled) in children &lt;12 years of age has not shown efficacy and may be associated with a higher risk of adverse effects. A study in children 5 to 11 years of age with mild to moderate persistent asthma evaluated quintupling the dose of the inhaled corticosteroid (fluticasone) following the early signs of decreased asthma control; results showed that quintupled fluticasone dosages did not reduce the rate of severe exacerbations and may have been associated with adverse effects (decreased linear growth, particularly in patients &lt;8 years of age) (Jackson 2018).</p></div>
<div class="block dosfc drugH1Div" id="F46518754"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Asmanex HFA inhaler delivers 120 actuations.</p></div>
<div class="block foc drugH1Div" id="F9461992"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol, Inhalation, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex HFA: 50 mcg/actuation (13 g); 100 mcg/actuation (13 g); 200 mcg/actuation (13 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (120 Metered Doses): 220 mcg/actuation (1 ea) [contains lactose, milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (120 Metered Doses): 220 mcg/actuation (1 ea [DSC]) [contains milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (14 Metered Doses): 220 mcg/actuation (1 ea) [contains lactose, milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (14 Metered Doses): 220 mcg/actuation (1 ea [DSC]) [contains milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (30 Metered Doses): 110 mcg/actuation (1 ea) [contains lactose, milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (30 Metered Doses): 110 mcg/actuation (1 ea [DSC]) [contains milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (30 Metered Doses): 220 mcg/actuation (1 ea) [contains lactose, milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (30 Metered Doses): 220 mcg/actuation (1 ea [DSC]) [contains milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (60 Metered Doses): 220 mcg/actuation (1 ea) [contains lactose, milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (60 Metered Doses): 220 mcg/actuation (1 ea [DSC]) [contains milk protein]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex (7 Metered Doses): 110 mcg/actuation (1 ea [DSC]) [contains lactose, milk protein]</p></div>
<div class="block geq drugH1Div" id="F9461868"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F9461994"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Asmanex HFA Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/ACT (per gram): $8.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/ACT (per gram): $9.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg/ACT (per gram): $10.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Asmanex (120 Metered Doses) Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mcg/ACT (per each): $202.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Asmanex (14 Metered Doses) Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mcg/ACT (per each): $46.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Asmanex (30 Metered Doses) Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">110 mcg/ACT (per each): $111.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mcg/ACT (per each): $120.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Asmanex (60 Metered Doses) Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 mcg/ACT (per each): $141.48</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871104"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asmanex Twisthaler: 100 mcg/actuation (1 ea); 200 mcg/actuation (1 ea); 400 mcg/actuation (1 ea) [contains lactose]</p></div>
<div class="block admp drugH1Div" id="F52614439"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:2em;">Asmanex Twisthaler (Dry powder inhaler): Remove inhaler from foil pouch; write date on cap label. Keep inhaler upright while removing cap, twisting in a counterclockwise direction; lifting the cap loads the device with the medication. Exhale fully prior to bringing the inhaler up to the mouth. Place inhaler in mouth, while holding it in a horizontal position. Close lips around the mouthpiece and inhale quickly and deeply. Remove the inhaler from your mouth and hold your breath for about 10 seconds, if possible. Do not exhale into inhaler. Wipe the mouthpiece dry and replace the cap immediately after each inhalation; rotate fully until click is heard. Rinse mouth with water (without swallowing) after inhalation to decrease chance of oral candidiasis. Avoid contact of the inhaler with any liquids; do not wash; wipe with dry cloth or tissue if needed. Discard the inhaler 45 days after opening foil pouch or when dose counter reads "00."</p>
<p style="text-indent:-2em;margin-left:2em;">Asmanex HFA (Metered dose inhaler): Shake well prior to use; administer as 2 inhalations twice daily (morning and evening). Prime the inhaler before first use by releasing 4 test sprays into the air, away from the face, shaking well before each spray. If the inhaler has not been used for more than 5 days, prime the inhaler again with 4 test sprays. Rinse mouth with water without swallowing (decreases the chance of oral candidiasis). Do not wash inhaler with water; clean mouthpiece using a dry cloth every 7 days and discard inhaler after the counter reaches “0”.</p></div>
<div class="block adm drugH1Div" id="F9461977"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Asmanex HFA: Metered-dose inhaler: Shake well prior to each inhalation. Administer as 2 inhalations twice daily (morning and evening). Prime before first use and when the inhaler has not been used for &gt;5 days by releasing 4 test sprays into the air, away from the face, shaking well before each spray. Rinse mouth with water (without swallowing) and spit after each use. Clean mouthpiece with a dry wipe after every 7 days of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Asmanex Twisthaler: Dry-powder inhaler: When administered once daily, administer only in the evening. Exhale fully, then place mouthpiece in mouth holding it in a horizontal position and inhale quickly and deeply. Remove inhaler and hold breath for 10 seconds if possible. Do not breathe out through the inhaler. Rinse mouth after use.</p></div>
<div class="block sts drugH1Div" id="F9461928"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Asmanex HFA: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not puncture. Do not use or store near heat or open flame; never throw container into fire or incinerator. Exposure to temperatures above 120°F may cause bursting. Discard when dose counter reads “0".</p>
<p style="text-indent:-2em;margin-left:2em;">Asmanex Twisthaler: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Discard when dose counter reads "00" or 45 days after opening the foil pouch, whichever comes first.</p></div>
<div class="block usep drugH1Div" id="F53570828"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Maintenance treatment of asthma as prophylactic therapy (Asmanex Twisthaler: FDA approved in ages ≥4 years and adults; Asmanex HFA: FDA approved in ≥5 years and adults); <b>NOT</b> indicated for the relief of acute bronchospasm.</p></div>
<div class="block cyt drugH1Div" id="F9461922"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F9461923"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Orally Inhaled) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mometasone (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May diminish the therapeutic effect of Corticosteroids (Orally Inhaled).<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F9461976"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Asmanex Twisthaler may contain lactose.</p></div>
<div class="block rep_considerations drugH1Div" id="F56788254"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Uncontrolled asthma may negatively affect fertility by increasing time to pregnancy and reducing birth rate. Fertility may be improved in patients adequately treated with inhaled corticosteroids (Couillard 2021; ERS/TSANZ [Middleton 2020]). Inhaled corticosteroids used for the treatment of asthma should not be discontinued in patients planning to become pregnant (GINA 2023). The lowest dose that maintains asthma control should be continued (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block pri drugH1Div" id="F9461910"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Maternal use of inhaled corticosteroids (ICS) in usual doses is not associated with an increased risk of fetal malformations; a small risk of malformations was observed in one study following high maternal doses of an alternative inhaled corticosteroid (ERS/TSANZ [Middleton 2020]).</p>
<p style="text-indent:0em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes) (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy. Due to the risk of exacerbations, stepping down or stopping ICS should not be done during pregnancy (GINA 2023). Mometasone oral inhalation is considered probably acceptable for use during pregnancy. Pregnant patients adequately controlled on mometasone for asthma may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant patients may be preferred. The lowest dose that maintains asthma control should be used. Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (OTIS) (877-311-8972 or http://mothertobaby.org). Patients may also enroll themselves.</p></div>
<div class="block mopp drugH1Div" id="F53570827"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor growth in pediatric patients (via stadiometry). Check mucous membranes for signs of fungal infection. Monitor asthma symptoms, FEV<sub>1</sub>, peak flow and/or other pulmonary function tests; HPA axis suppression; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma); bone mineral density.</p></div>
<div class="block pha drugH1Div" id="F9461929"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilatation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.</p></div>
<div class="block phk drugH1Div" id="F9461931"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Maximum effects may not be evident for ≥1 to 2 weeks</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration after discontinuation: Several days or more</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: &lt;1%; clinical effects are due to direct local effect, rather than systemic absorption</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 152 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 98% to 99%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensive in the liver to multiple metabolites; no major metabolites are detectable in the plasma; in vitro incubation studies identified one minor metabolite, 6 Beta-hydroxymometasone furoate, formed via cytochrome P450 CYP3A4 pathway </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Single dose: &lt;1%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Mean: 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 0.5 to 2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~74%), urine (~8%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23669751"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Avocom | Momate | Mometix AQ | Nasehaler | Nasonex | Natazone | Rinelon | Sinocort | Tabunex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fenisona | Hexaler | Lisiker | Metason | Nasonex | Suavicort | Uniclar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mometason cipla | Mometason Hexal | Mometason ratiopharm | Nasonex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal mometasone nasal allergy relief | Apo mometasone | Azonaire | Blooms the chemist mometasone nasal allergy relief | Chemmart mometasone | Medifess | Metaspray | Nasonex | Nasonex allergy | Pharmacy care mometasone nasal allergy relief | Pharmacy choice hayfever prevention &amp; relief | Priceline pharmacy mometasone allergy relief | Sensease nasal allergy relief | Telnasal | Terry white chemists mometasone | Uniclar aqueous nasal spray</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Metaspray | Momeson | Nasomet | Nasonex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Momepax | Mometasone cipla | Mometasone sandoz | Mometasone teva | Mometeva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Nasehaler | Nasonex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bloctimo | Etacid | Kalmente | Momanose | Mometasone | Nasonex | Nasostad</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amome | Furoato de mometasona | Momate | Monax | Nasonex | Nites | Ventus</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mometason mepha | Mometason pollen sandoz | Mometason spirig hc | Mometasonfuroat sandoz</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Nasehaler</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dimuxon | Monez | Nasonex | Pluster | Rinitek | Rinomase | Rinoval | Suavicort | Synaller | Uniclar</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Biometasona | Broner | Furoato de mometasona | Furomet | Metaspray | Momenase | Mometasona | Mometasyn | Mometasyn free | Nasonex | Rhinospray | Rinosal | Rinosona | Uniclar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Asmanex | Momanose | Momespir | Mometason furoat actavis | Mometason furoat cipla | Mommox | Nasonex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Allergo momelind | Aphiasone | Momeallerg | Momegalen | Momekort | Mometadex | Mometahexal | Mometason beta | Mometason ratiopharm heuschnupfenspray | Mometasonfuroat AbZ | Mometasonfuroat al | Mometasonfuroat ratiopharm | Nasonex | Vividrin Mometason</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aguanace | Furonasal | Metaspray | Mometasona sandoz | Mometasyn | Mometasyn free | Mommex | Nasonex | Plermin | Rinetason | Rinix | Rinobudex | Rinolerg | Uniclar</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Furoato de mometasona | Metacross | Metasone | Momate ns | Mometasona | Mometasona la sante | Monez | Nasonex | Plenium | Rinetason | Rinobudex | Rinoval | Uniclar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Breso | Kalmente | Mometasone sanoswiss | Nasometin | Nasonex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nasonex | Norhinose | Tabunex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mometasona | Mometasona aldo union | Mometasona furoato cinfa | Mometasona furoato cipla | Mometasona furoato Stadagen | Mometasona furoato vir | Mometasona kern | Mometasona sandoz | Mometasona teva | Nasoaldo | Nasonex | Rinelon</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Etacid | Nasonex | Tabunex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Momesonex | Mometasone actavis | Mometasone cipla | Mometasone orion | Mommox | Nasonex | Nenoxin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mometasone arrow | Mometasone biogaran | Mometasone cristers | Mometasone eg | Mometasone gerda | Mometasone mylan | Mometasone sandoz | Mometasone zentiva | Nasonex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Asmanex | Clarinaze allergy | Mometasone | Mometasone teva | Nasonex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mometasone target | Nasonex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo mometasone | Metaspray | Momeson | Nasonex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bloctimo</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bloctimo | Kalmente | Mometason pannonpharma | Mometason Sandoz | Mometasone cipla | Nasonex | Nasotasone</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Modexa | Nasonex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nasonex | Rhinex relief</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Nasonex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aquamet | Ezispray | M-Spray | Megaspray | Metaspray | Metatop | Momefit | Momenta | Momist | Msone | Nasonex | Nazomac M | Respizen | Sensonase</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Brexcort | Brusonex | Calimix | Emmarin | Exicort | Metacort | Momecort | Mometasone cipla | Mometasone eurogenerici | Mometasone furoato sandoz | Mometasone teva | Mometasone zentiva | Momil | Nasonex | Rinelon | Rinoff | Uniclar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alivio | Aresil | Nasonex | Sinocort | Tabunex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mometasone ceo | Mometasone jg | Mometasone kyorin | Mometasone myl | Mometasone nitto | Mometasone takata | Mometasone towa | Nasonex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Momate | Momecort | Momeson | Nasonex | Rhinizill | Sinocort</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alernasal | Antirun | Aranex | Biconex | Biconex nasal | Bizonex | Br conex | Ckd mometasone furoate | Cobinex | Cobizal | Coco | Coetasone | Coezal | Cozalnex | I meta | Jw mometasone | Kometasone | Mobeta | Momeco | MomeCT | Momet | Mometal | Mometaon | Mometasone | Monasone | Monitazon | Moritasone nasal | Motanex | Motesone | Nacodrin | Narinex | Nasacare | Nasativ | Nasative | Nasoclean | Nasocobi | Nasocure | Nasomega | Nasomesone | Nasonex | Nasotasone | Nazatasone | Nazocobi | Nazometa | Neriex | New naso a | Nezelex | Raninex | Rb pro | Rhinex | Rhinonex | Samsung mometasone | Schnell | Zalconex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mometix AQ | Nasonex aqueous | Tabunex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Avocom | Metasone | Metaspray | Nasonex | Sinocort | Tabunex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Breso | Kalmente | Mometasone furoate sandoz | Mometasone inteli | Mometasone sandoz | Mometasone teva | Nasometin | Nasonex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mometasone sandoz | Nasonex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Breso | Mometasone teva | Nasometin | Nasonex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Metanaz | Nasonex | Risonel | Tabunex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Akira | Alegoria | Dimuxon | Dirnelid | Dutina | Levante | Modinaxfar | Mofhinis | Mometasona | Quimafron | Rinelon | Uniclar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo mometasone furoate | Axcel mometasone | Elonide | Metaspray | Momate | Nasehaler | Nasonex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mometason Furoaat | Mometasonfuroaat Aurobindo | Mometasonfuroaat cf | Mometasonfuroaat Cipla | Mometasonfuroaat fisher | Mometasonfuroaat Sandoz | Mometasonfuroaat teva | Nasonex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mometason cipla | Mometason ratiopharm | Mometasone sandoz | Nasonex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Azonaire</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Momate | Mometasyn | Mometax n | Nasonex | Nasonex pediatrico | Plermin | Rinelon | Rinobudex | Suavicort</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Metaspray | Momate | Mosaspray | Nasonex | Rinelon | Zymocort</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Hivate | Mms | Nasomet | Rinelon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aleric | Eztom | Hitaxa metmin | Momester | Nasehaler | Nasometin | Nasometin Control | Nasonex | Pronasal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Asmanex hfa | Nasonex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mometasona alter | Mometasona generis | Mometasona Ratiopharm | Mometasona sandoz | Mometasona teva | Nasomet | Rhinizill</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aerostan | Alersona | Hexaler nasal | Metason | Momenta | Momesona | Mometasyn free | Nasolin | Rinoval | Suavicort</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Asmanex Twisthaler</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kalmente | Mometazona teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dezrinit | Momate rhino | Momenza | Mometasone sandoz | Momezal allergo | Nasonex | Nozefrin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Avocom | Defonex | Momate | Nasonex | Nosco | Tabunex | Tasonex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aphiahsone | Momenex | Mometason ABECE | Mometason apofri | Mometason Evolan | Mometasone actavis | Mometasone orion | Mometasone teva | Mommox | Nasonex | Orimox</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mometasone sandoz | Nasonex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mommox | Mommox rino | Nasonex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mometasone actavis | Mometasone furoate cipla | Mometasone sandoz | Mometazon teva | Nasometin | Nasonex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mometasone sandoz | Nasonex | Rinelon</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Mesone | Nasomet | Nasonex | Risomax | Sinocort</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avixonel | Etacid | K allexin | Momecon | Mometix AQ | Monaliz | Myrey | Nasonex | Nazofix | Risonel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Momenase</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Allertec nazo | Asmanex | Canomen | Etacid | Flix | Forinex | Glenspray | Mometason teva | Mometasone | Momixon | Nasonex | Nasonex sinus</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Momenap | Nasehaler | Nasonex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Nasonex | Suavicort</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Elocon | Metaspray | Momnase | Nasoaldo | Nasonex | Nimarin | Uniclar</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Mome Air</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mometasone clicks | Monact | Nasonex aqueous | Nexomist | Rinelon | Zilfone</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Momenap</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Nasehaler</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AsmanexHFA.1">
<a name="AsmanexHFA.1"></a>Asmanex HFA (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AsmanexTwisthaler.1">
<a name="AsmanexTwisthaler.1"></a>Asmanex Twisthaler (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; September 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AsmanexTwisthaler.2">
<a name="AsmanexTwisthaler.2"></a>Asmanex Twisthaler (mometasone furoate) [prescribing information]. Jersey City, NJ: Organon LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AsmanexTwisthaler.3">
<a name="AsmanexTwisthaler.3"></a>Asmanex Twisthaler (mometasone furoate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16159616">
<a name="16159616"></a>Bakhireva LN, Jones KL, Schatz M, et al, “Asthma Medication Use in Pregnancy and Fetal Growth,” <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/16159616/pubmed" id="16159616" target="_blank">16159616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34646341">
<a name="34646341"></a>Couillard S, Connolly C, Borg C, Pavord I. Asthma in pregnancy: an update. <i>Obstet Med</i>. 2021;14(3):135-144. doi:10.1177/1753495X20965072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/34646341/pubmed" id="34646341" target="_blank">34646341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.3">
<a name="GINA.3"></a>Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. https://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/. Updated 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Updated 2019. Accessed December 13, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al. Risk Factors for Classical Kaposi's Sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29504498">
<a name="29504498"></a>Jackson DJ, Bacharier LB, Mauger DT, et al. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. <i>N Engl J Med</i>. 2018;378(10):891-901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/29504498/pubmed" id="29504498" target="_blank">29504498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29504499">
<a name="29504499"></a>McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. <i>N Engl J Med</i>. 2018;378(10):902-910. doi:10.1056/NEJMoa1714257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/29504499/pubmed" id="29504499" target="_blank">29504499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12108877">
<a name="12108877"></a>Todd GR, Acerini CL, Buck JJ, et al, "Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate," <i>Eur Respir J</i>, 2002, 19(6):1207-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/12108877/pubmed" id="12108877" target="_blank">12108877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12456538">
<a name="12456538"></a>Todd GR, Acerini CL, Ross-Russell R, et al, "Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom," <i>Arch Dis Child</i>, 2002, 87(6):457-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/12456538/pubmed" id="12456538" target="_blank">12456538</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16022 Version 212.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
